A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Latest Information Update: 07 Apr 2021
At a glance
- Drugs Eribulin (Primary) ; Dacarbazine
- Indications Leiomyosarcoma; Liposarcoma; Myxoid liposarcoma; Soft tissue sarcoma
- Focus Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd; Eisai Inc
- 01 Apr 2021 Results of an exploratory molecular analysis published in the Clinical Cancer Research
- 24 Jun 2020 Results assessing the molecular profile of LMS tumors from North American study sites assessing to identify potential predictive molecular factors for treatment with eribulin, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
- 08 May 2019 Results of a sub-group analysis assessing eribulin versus dacarbazine in patients with leiomyosarcoma (n=309) published in the British Journal of Cancer